 |
3 Diseases |  |
1 Trial |
|
1 Trial |  |
23 News |  |
- | INV103 / Invion
Journal: Molecular Characterization of Heat-Induced HSP11.0 and Master-Regulator HSF from Cotesia chilonis and Their Consistent Response to Heat Stress. (Pubmed Central) - May 1, 2021
CcHSP11.0 contained a chaperonin cpn10 signature motif that is conserved in other hymenopteran insects...Overall, the induction of Cchsf was lower than Cchsp11.0 at low temperatures, whereas the opposite was true at high temperatures. In conclusion, both Cchsp11.0 and Cchsf are sensitive to high and low temperature stress, and the expression pattern of the two genes were positively correlated during temperature stress.
- | INV103 / Invion
Journal: Sequence analysis and protein interactions of Arabidopsis CIA2 and CIL proteins. (Pubmed Central) - Jul 9, 2020
In conclusion, both Cchsp11.0 and Cchsf are sensitive to high and low temperature stress, and the expression pattern of the two genes were positively correlated during temperature stress. We show that Arabidopsis CIA2 and CIL can interact with CO and NF-Y complex, so not only may they contribute to regulate chloroplast function but also to modulate flower development.
- | INV103 / Invion
Preclinical, Journal: Effect of Tim23 Knockdown in vivo on Mitochondrial Protein Import and Retrograde Signaling to the UPRmt in Muscle. (Pubmed Central) - Jul 4, 2019
...This import defect activated the C/EBP homologous protein (CHOP) branch of the UPR, as evident from increases in caseinolytic mitochondrial matrix peptidase proteolytic subunit (ClpP) and chaperonin 10 (cpn10) but not the activating transcription factor 5 (ATF5) arm...Our data suggest that mitochondrial proteolytic byproducts exert an inhibitory effect on protein import, possibly to reduce excessive protein import as a potential negative feedback mechanism. The inhibition of import into the organelle also serves a retrograde function, possibly via ROS emission, to modify nuclear gene expression and ultimately improve folding capacity.
- | INV103 / Invion
Trial completion, Enrollment change: Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE. (clinicaltrials.gov) - Sep 9, 2015
P1/2, N=29, Completed, Sponsor: Invion, Inc.
The inhibition of import into the organelle also serves a retrograde function, possibly via ROS emission, to modify nuclear gene expression and ultimately improve folding capacity. Active, not recruiting --> Completed | N=40 --> 29
- | INV103 / Invion
Enrollment closed: Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE. (clinicaltrials.gov) - Aug 27, 2015
P1/2, N=40, Active, not recruiting, Sponsor: Invion, Inc.
Active, not recruiting --> Completed | N=40 --> 29 Recruiting --> Active, not recruiting
- INV103 / Invion
Trial primary completion date: Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE. (clinicaltrials.gov) - Apr 15, 2015
P1/2, N=40, Recruiting, Sponsor: Invion, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2015 --> Oct 2015
- INV103 / Invion
Trial primary completion date: Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE. (clinicaltrials.gov) - Jan 28, 2015
P1/2, N=40, Recruiting, Sponsor: Invion, Inc.
Trial primary completion date: Mar 2015 --> Oct 2015 Trial primary completion date: Dec 2014 --> Mar 2015
- | INV103 / Invion
Enrollment change: Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE. (clinicaltrials.gov) - Oct 17, 2014
P1/2, N=40, Recruiting, Sponsor: Invion, Inc.
Trial primary completion date: Dec 2014 --> Mar 2015 N=32 --> 40
- INV103 / Invion
Trial primary completion date: Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE. (clinicaltrials.gov) - Jun 22, 2014
P1/2, N=32, Recruiting, Sponsor: Invion, Inc.
N=32 --> 40 Trial primary completion date: Jul 2014 --> Oct 2014
- | INV103 / Invion
Enrollment open: Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE. (clinicaltrials.gov) - Jul 15, 2013
P1/2, N=32, Recruiting, Sponsor: Invion, Inc.
Trial primary completion date: Jul 2014 --> Oct 2014 Not yet recruiting --> Recruiting
- | INV103 / Invion
New P1/2 trial: Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE. (clinicaltrials.gov) - Apr 22, 2013
P1/2, N=32, Recruiting, Sponsor: Invion, Inc.